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Abstract
SAFB1 is a DNA and RNA binding protein that is highly expressed in the cerebellum 
and hippocampus and is involved in the processing of coding and non-coding RNAs, 
splicing and dendritic function. We analyzed SAFB1 expression in the post-mortem 
brain tissue of spinocerebellar ataxia (SCA), Huntington’s disease (HD), Multiple scle-
rosis (MS), Parkinson’s disease patients and controls. In SCA cases, the expression of 
SAFB1 in the nucleus was increased and there was abnormal and extensive expression 
in the cytoplasm where it co-localized with the markers of Purkinje cell injury. Sig-
nificantly, no SAFB1 expression was found in the cerebellar neurons of the dentate 
nucleus in control or MS patients; however, in SCA patients, SAFB1 expression was 
increased significantly in both the nucleus and cytoplasm of dentate neurons. In HD, 
we found that SAFB1 expression was increased in the nucleus and cytoplasm of striatal 
neurons; however, there was no SAFB1 staining in the striatal neurons of controls. In 
PD substantia nigra, we did not see any changes in neuronal SAFB1 expression. iCLIP 
analysis found that SAFB1 crosslink sites within ATXN1 RNA were adjacent to the 
start and within the glutamine repeat sequence. Further investigation found increased 
binding of SAFB1 to pathogenic ATXN1-85Q mRNA. These novel data strongly 
suggest SAFB1 contributes to the etiology of SCA and Huntington’s chorea and that 
it may be a pathological marker of polyglutamine repeat expansion diseases.
INTRODUCTION
RNA binding proteins (RBPs) play an important regulatory 
role in cellular metabolism by defining the complex interac-
tions of coding, structural and regulatory RNA species (23). 
Recent studies have found that mutations in specific RBPs 
cause amyotrophic lateral sclerosis (ALS) and some forms 
of ataxia (4,17). As neurons are post-mitotic and have highly 
complex transcriptomes, they will be particularly susceptible 
to the changes in gene regulation brought about by altered 
RBP function. This hypothesis is supported by recent find-
ings suggesting that altered RBP function contributes to 
the death of neurons seen in polyglutamine (polyQ) expan-
sion diseases (e.g. spinocerebellar ataxia type 1 (SCA1) and 
Huntington’s disease (HD)) (4,25). Historic evidence suggested 
that HD was caused by the mutant huntingtin protein 
(mHTT) losing function and due to the formation of neu-
rotoxic fragments of mHTT (5). However, the sequestration 
of RBPs by the translated mutant proteins has also been 
shown to contribute to pathology due to a loss and/or 
toxic gain of RBP function (reviewed by (9,37). Proteins 
containing a pathological number of polyglutamine repeats 
(e.g. huntingtin and ataxin-1) are reported to lose normal 
functions and/or gain toxic functions due to the aberrant 
binding of proteins involved in the control of transcription, 
splicing and RNA processing (9,22). Expansions in poly-
glutamine and hexanucleotide repeat regions have recently 
been shown to be translated by repeat-associated non-ATG 
translation (RAN translation). RAN translation produces 
chains of dipeptide protein that are bound by RBPs and 
further implicates alerted RBP function in disease pathology 
(6,19,26,34). Furthermore, mutations in the RBPs, TDP-43 
(14), FUS (43) and MATR3 (13) have also been found to 
cause ALS directly linking altered RBP function in the 
etiology of human neurodegenerative illnesses.
Scaffold attachment factor B1 (SAFB1) is a DNA and 
RNA binding protein first identified on the basis of its ability 
to bind scaffold attachment regions (27) and as a repressor 
of the Hsp27 promoter DNA elements (30). Subsequent to 
these findings, its role as a tumor suppressor was investigated 
(29) and it was found to play a role in DNA repair (2). 
More recently the neuronal functions of SAFB1 were inves-
tigated and it was found to be expressed in the CNS with 
expression levels being particularly high in the hippocampus 
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and cerebellum (28). In addition, analyses of SAFB1’s neuronal 
RNA binding partners showed that SAFB1 bound primarily 
within exon sequences, 3′UTRs and with miRNAs and long 
non-coding RNAs (35). This work also showed that SAFB1 
bound purine-rich motifs to regulate the splicing of neuronal 
genes and that it regulated dendritic spine formation (35). 
SAFB1 was also recently reported to be required for FUS 
to regulate splicing (46) and to interact with the LC-3 con-
jugation machinery to load extracellular vesicles (EVs)(21). 
As SAFB1 shares properties with RBPs known to be impli-
cated in human neurodegenerative disease, is expressed at high 
levels in the cerebellum, translocates to nuclear stress bodies 
(nSBs) following the exposure of cells to a variety of stresses 
and binds ATXN1 we investigated its expression in SCAs 
alongside other neurodegenerative diseases.
MATERIALS AND METHODS
Donor tissue
Post-mortem formalin-fixed paraffin-embedded (FFPE) sections 
from patients diagnosed with SCA, HD, PD and control cases 
with no history of neurological disease were obtained from 
the MRC London Neurodegenerative Diseases Brain Bank. 
Donor tissue was collected via a prospective donor scheme 
and utilized in this study under ethics approval number 
LNDBB1778. Cerebellar tissue sections from patients diagnosed 
with multiple sclerosis were obtained from the Multiple Sclerosis 
Tissue Bank, Imperial College, London, UK and utilized in 
this study under research ethics committee approval 08/
MRE09/31. Post-mortem donor brain tissue was fixed in neu-
tral buffered formalin and embedded in paraffin. Tissue sec-
tions were cut to between 7 and 10  µm and mounted onto 
glass slides. Details of all patient cases are given in Table 1.
Immunohistochemical staining of human brain 
tissue
Formalin-fixed paraffin-embedded (FFPE) sections were 
immunostained with rabbit anti-SAFB1 antibody (1:50) 
(A300-811A,  Bethyl  Laboratories, UK), or mouse anti-
polyglutamine antibody (1:1000) (1C2, Millipore). Sections 
were deparaffinized in Histo-clear and rehydrated in graded 
alcohol solutions. Antigen retrieval was carried out by micro-
waving slides immersed in 0.1mM sodium citrate buffer (pH 
Table 1. Clinicopathological details of donor cases used in this study.
Case Brain region Pathological diagnosis Age (years) PMD (h) Sex (M/F) Cause of death
1 Cerebellum Control 74 66 F Pneumonia
2 Cerebellum Control 90 45 M Myocardial infarction
3 Cerebellum Control 66 78 F Metastatic colorectal cancer
4 Cerebellum Control 65 26 M Metastatic prostate cancer
Mean 73.8 53.8 50%
SEM 5.8 11.5 F
5 Cerebellum SCA1 76 24 M Cancer (unknown primary)
6 Cerebellum SCA 54 31.5 F Not available
7 Cerebellum SCA 68 48 M Not available
8 Cerebellum SCA 74 33 F Not available
9 Cerebellum SCA 86 Not available M Bronchopneumonia
Mean 71.6 34.1 60%
SEM 5.3 5 F
10 Striatum Control 51 33 F Lung cancer
11 Striatum Control 63 23 M Colon cancer
12 Striatum Control 89 43 F Cancer
13 Striatum Control 85 45 M Urethral cancer
14 Striatum Control 65 26 M Metastatic prostate cancer
15 Striatum Control 82 47 M Congestive cardiac failure
16 Striatum Control 84 34 F Sepsis; metastatic breast cancer
Mean 74.1 35.9 43%
SEM 5.4 3.6 F
17 Striatum HD (grade 2) 83 55 F Myocardial infarction
18 Striatum HD (grade 2) 79 26 M Huntington’s disease
19 Striatum HD (grade 3) 54 19 M Huntington’s disease
20 Striatum HD (grade 3) 57 66 F Bronchopneumonia
21 Striatum HD (grade 3) 83 24 F Not available
22 Striatum HD (grade 4) 64 47 M Not available
23 Striatum HD (grade 4) 55 60 F Not available
24 Striatum HD (grade 4) 79 45 F Acute myocardial infarction
Mean 69.3 42.8 63%
SEM 4.6 6.3 F
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6) with 0.05% (v/v) Tween 20 until boiling. Slides were left 
to stand for 5 minutes, re-heated again and boiled for 1 
min, left to cool in buffer for 20  minutes and then trans-
ferred to running tap water. Endogenous peroxidases were 
neutralized by incubating sections for 15  minutes in 1% 
hydrogen peroxide diluted in distilled water. Immunoh-
istochemical staining was carried out using an avidin–biotin 
complex staining kit (VECTASTAIN Elite ABC HRP Kit 
(Peroxidase, Universal), PK-6200, Vector Laboratories). After 
washing in phosphate-buffered saline (PBS pH 7.4) with 
0.05% (v/v) Triton X-100, non-specific binding was blocked 
using normal horse serum (VECTASTAIN blocking solu-
tion) diluted 1:100 in PBS-T for 45  minutes. Sections were 
incubated with primary antibody diluted in blocking solution 
overnight at 4°C. Sections incubated in antibody diluent 
only served as no primary antibody controls. Sections were 
washed in PBS, then incubated in secondary antibody 
(VECTASTAIN biotinylated horse anti-rabbit/mouse, 1:50) 
diluted in VECTASTAIN blocking solution. Following PBS 
washes, sec tions were incubated in ABC reagent 
(VECTASTAIN Elite ABC Reagent, 1:50) and antibody bind-
ing was visualized using 3,3′-diaminobenzidine (DAB) 
(Vectorlabs DAB substrate kit, no nickel). After washing in 
distilled water, nuclei were visualized by counterstaining in 
Ehrlich’s hematoxylin, before rinsing slides in running tap 
water. Sections were dehydrated in graded alcohol solutions, 
cleared in xylene and mounted under glass coverslips using 
DPX mountant. Image capture was carried out using a Nikon 
eclipse i80 microscope with Nikon Ci-SMS camera, and Image-
Pro plus software, or using an Aperio Scanscope CS2 digital 
slide scanner (Leica) and Leica ImageScope software.
Immunofluorescent labeling of human brain 
tissue
Slides were dewaxed in Clearene, immersed in 100% alcohol 
then washed in running tap water for 10 minutes. Antigen 
retrieval was carried out as described for immunohistochemi-
cal staining. Slides were washed in running tap water, then 
washed in PBS (pH 7.4). Protein block was carried by 
incubating with protein blocking solution (10% normal goat 
serum diluted in PBS with 0.01% Triton X-100) for 1 hour 
at room temperature. Sections were double immunolabeled with 
rabbit anti-SAFB1 (1:200) (A300-811A, Bethyl Laboratories) 
and either mouse anti-calbindin-D-28K (1:500) (Sigma-
Aldrich, UK) or mouse anti-SMI-34 (hyperphosphorylated 
neurofilament, 1:500) (Covance, US). Sections were incubated 
in primary antibodies diluted in blocking solution overnight 
at 4°C. Sections were washed in PBS before incubation 
with fluorescently conjugated secondary antibodies diluted 
in blocking solution for 1 hour at room temperature, pro-
tected from light (Alexa Fluor 488 goat anti-rabbit (1:500) 
or Alexa Fluor 555 goat anti-mouse (1:500) (Invitrogen, 
UK)). Sections were washed in PBS, then incubated with 
DAPI (1  µg/mL in PBS) (Thermo Fisher Scientific, UK) 
for 5  minutes. Following a final PBS wash, sections were 
mounted in 50% PBS/50% glycerol under glass coverslips 
sealed with clear nail varnish. Slides were stored at 4°C in 
the dark prior to imaging using a Nikon C1 confocal micro-
scope with EZ viewer software.
Analysis of SAFB1 immunohistochemistry  
in cerebellar Purkinje cells
Prior to all immunohistochemical analyses, sections were 
coded and the investigator blinded to their identity. The 
analysis of  Purkinje cells was based on our previous method 
(15). To analyze DAB immunolabeling of SAFB1 in Purkinje 
cells, cerebellar sections were scanned using an Aperio 
Scanscope digital slide scanner. The Purkinje cell layer 
was traced and the distance measured using annotation 
tools within the Aperio ImageScope software. Purkinje 
cells were identified by their characteristic morphology 
and localization within the cerebellar sections. The peri-
karyon of  each Purkinje cell that had a clearly visible 
nucleus was traced and the area in µm2 of  each perikaryon 
measured. Each Purkinje cell was categorized as either 
positive (brown staining) or negative (no brown staining) 
for SAFB1 immunoreactivity within the nucleus and 
cytoplasm.
Analysis of SAFB1 immunohistochemistry  
in cerebellar white matter neurons
To analyze DAB immunolabeling of SAFB1 in large neurons 
within cerebellar white matter, the dentate nucleus was iden-
tified at low microscopic magnification as a characteristic 
grey matter ribbon running through the cerebellar white 
matter. Images were taken at regular intervals along the 
whole of the dentate nucleus tissue tract within each sec-
tion. A minimum of 15 images was acquired per section. 
Large principle neurons were identified within each image 
by their characteristic size and morphology and graded as 
either positive or negative for SAFB1 immunoreactivity within 
the nucleus and cytoplasm.
Analysis of SAFB1 immunohistochemistry  
in striatum
To analyze DAB immunolabeling of SAFB1 in the striatum, 
images were captured at 20x magnification from across the 
whole stained striatal section.  A minimum of 15 images 
was  analyzed per section.  The number of cells containing 
SAFB1 immunoreactivity in the nucleus, cytoplasm, or both, 
were counted manually using ImageJ software.  For polyglu-
tamine (1C2) staining, the number of cells positive for 
immunopositivity in either the nucleus or cytoplasm was 
counted manually using Image J software.
Individual-nucleotide resolution UV 
crosslinking and immunoprecipitation (iCLIP)
To identify the RNA binding partners of SAFB1 iCLIP 
experiments in triplicate were performed as previously 
described (1,35). The filtered iCLIP tag sequences were 
mapped to the human genome sequence (version hg19/
Buckner et alAbnormal SAFB1 Expression in PolyQ Diseases
Brain Pathology 0 (2020) 1–15
© 2020 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology.
4
GRCh37) allowing one mismatch using Bowtie version 1.0.1. 
Comparing cross-link nucleotide positions from three inde-
pendent replicates assessed reproducibility and allowed the 
Z-score analysis of enriched pentamers at cross-link nucleo-
tides to be calculated (1,35).
Transfection of HeLa cells with ATXN1 plasmids
HeLa cells grown in high-glucose DMEM (supplemented 
with 10% v/v fetal bovine serum and 10  mM l-glutamine) 
were plated at a density of 900  000 cells/10  cm culture 
dish. After 24  h, HeLa cells were transfected with DNA 
plasmids containing FLAG-tagged ataxin1 (ATXN1) with 
either a normal CAG repeat tract (pcDNA1 Flag ATXN1 
[30Q]) or a pathologically expanded CAG repeat tract (pcDNA1 
Flag ATXN1[85Q]). pcDNA1 Flag ATXN1[30Q] and pcDNA1 
Flag ATXN1[85Q] were kind gifts from Huda Zoghbi (41) 
(Addgene plasmid #33236 and #33237, respectively). 
Transfections were carried out in Opti-MEM reduced serum 
media (Thermo Fisher Scientific), using FuGENE 6 (Promega) 
transfection reagent according to the manufacturer’s instruc-
tions. A full media change was carried out 6 hours after 
transfection and cells were left for 48 hours before use in 
RNA immunoprecipitation experiments.
RNA immunoprecipitation
All stages of the RNA immunoprecipitation procedure were 
carried out in RNase-free conditions. HeLa cells were washed 
in ice-cold PBS and scraped on ice in 1ml of lysis buffer 
containing protease inhibitors and RNAse inhibitors. Lysates 
were centrifuged and the supernatant pre-cleared by incubat-
ing with protein G magnetic beads (Dynabeads, Thermo 
Fisher Scientific) washed in lysis buffer. Pre-cleared protein 
lysates were quantified using a bicinchoninic acid assay (Pierce 
BCA protein assay kit, Thermo Scientific). About 500  µg 
of protein was incubated with protein G beads which had 
been previously cross-linked to either a SAFB1 antibody 
(AB1895, Invitrogen custom antibody services) or concen-
tration-matched rabbit IgG (Cell Signalling Technology). 
Lysates were rotated overnight at 4°C with antibody-linked 
beads. Protein G beads bound to SAFB1 immunocomplexes 
were isolated from lysates using a magnetic rack and washed 
multiple times in lysis buffer. A sample of beads in solution 
from each experimental condition was reserved for analysis 
by Western blotting. Beads were pelleted and resuspended 
in BL/TG buffer from a ReliaPrep RNA Cell Miniprep kit 
(Promega) to dissociate immunocomplexes from protein G 
beads. RNA was purified from immunocomplexes using a 
ReliaPrep RNA Cell Miniprep Kit according to the manu-
facturer’s instructions.
Quantification of ATXN1 RNA by qPCR
RNA was reverse transcribed using a GoScript Reverse 
Transcription System kit (Promega) using random primers 
according to the manufacturer’s instructions. cDNA was 
analyzed by qPCR with Power SYBR Green (Thermo Fisher 
Scientific) primers specific to ATXN1 (F:TCCAGCACCG 
TAGAGAGGAT, R:GCCCTGTCCAAACACAAAAA) with 
a StepOnePlusTM PCR system (Thermo Fisher Scientific). 
The relative level of ATXN1 expression was calculated by 
comparing CT values to that of a standard curve of seri-
ally diluted ATXN1 DNA and normalized per µg of SAFB1 
protein. Relative ATXN1 expression for each condition was 
normalized to the mean ATXN1 expression level within 
each experimental replicate.
Western blotting of protein lysates from RNA 
immunoprecipitation experiments
To confirm SAFB1 protein was successfully isolated using 
antibody-linked protein G beads, samples of pre-cleared 
input were run alongside samples of antibody-linked and 
IgG-linked protein G beads associated with immunocom-
plexes. Beads were resuspended in SDS sample buffer and 
heated at 95°C for 5 minutes to dissociate protein from the 
beads. Samples were run on an 8% polyacrylamide gel then 
transferred to a PVDF membrane using a Trans-Blot Turbo 
Transfer System (Bio-Rad). Membranes were blocked in 5% 
milk then probed with anti-SAFB1 antibody (1:1000) (A300-
811 A, Bethyl Laboratories, UK) overnight at 4°C. Membranes 
were incubated with anti-rabbit peroxidase-conjugated sec-
ondary antibody (1:10  000) (GE Healthcare) and antibody 
signal visualized using ECL.
Statistical analysis
Statistical tests were performed in GraphPad Prism 
(GraphPad Software Inc., version 7.04). For all tests, 
P < 0.05 represented statistical significance. Unpaired, two-
tailed t-tests were used to compare data between the two 
groups. When comparing patient clinicopathological details 
between groups, the ages of  control cerebellar tissue donors 
(cases 1-4) were compared against the ages of  SCA cerebel-
lar tissue donors (cases 5-9) using an unpaired, two-tailed 
t-test. The post-mortem delay (PMD) of  the control and 
SCA cases was also compared by t-test. T-tests were also 
used to compare the age and PMD of  control striatal 
tissue donors (cases 10-16) and HD tissue donors (cases 
17-24). Results of  t-tests are reported as t(degrees of  free-
dom)  =  t-value, p value. All bar graphs represent the 
mean  ±  standard error of  the mean (SEM). Where mean 
values are presented on graphs, the data from individual 
cases are represented by a circle (for control cases) or 
square (for disease cases) symbol. Relationships between 
two sets of  data were analyzed using Pearson’s correlation 
tests.
RESULTS
Abnormal expression of SAFB1 in SCA is a 
novel histopathological hallmark
Immunohistochemical characterization of SAFB1 expression 
was carried out in cerebellar tissue from patients diagnosed 
with SCA and compared to the cerebellum from control 
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cases with no history of neurological disease (Tables 1 and 
S1). There was no significant difference in the age (t(7) = 0.27, 
P  =  0.79) or post-mortem delay (t(6)  =  1.57, P  =  0.17) 
of the SCA patients when compared to the controls (unpaired, 
two-tailed t-tests). It should be noted that one of the patients 
was genetically confirmed as SCA1, one had a family his-
tory of autosomal dominant SCA and another was confirmed 
as having polyglutamine inclusions. Two of the patients were 
diagnosed as SCA patients based on presentation and post-
mortem pathology (Table S1). The SAFB1 antibody used 
for immunostaining was previously shown to be specific for 
SAFB1 (Rivers et al, 2015) and control staining with no 
primary antibody was negative (Figure S1). SAFB1 immu-
nopositivity in Purkinje cells was quantified by counting 
the percentage of Purkinje cells positive for SAFB1 across 
whole sections (Figure 1). Low power photomicrographs 
(Figure S2) show Purkinje cells within the PC layer juxta-
posed with the molecular and granule cell layer (as indicated 
in Figure 2). The percentage of Purkinje cells with nuclear 
SAFB1 immunopositivity was not significantly different in 
the SCA patient tissue compared to control (Figure 1B). 
There was, however, a significantly higher percentage of 
Purkinje cells with cytoplasmic SAFB1 staining in SCA 
patients compared to controls (Figure 1C). We further 
Figure 1. Abnormal expressed of SAFB1 in cerebellar Purkinje cells is a 
feature of SCAs. A. Representative images of Purkinje cells 
immunostained for SAFB1. In control cases, cells show SAFB1 
expression in the nucleus but not in the cytoplasm. In SCA patients, 
Purkinje cells stain strongly for SAFB1 in the nucleus and feature 
abnormal SAFB1 expression in the soma and dendrites. Inset numbering 
represents the patient case number, scale bar is 25  µm. SAFB1 
immunostaining was quantified by counting the percentage of Purkinje 
cells with immunopositivity in either the nucleus or cytoplasm. B. There 
is no difference between the percentage of cells positive for nuclear 
SAFB1 in SCA patients compared to control. C. There is a significant 
increase in the frequency of SAFB1 cytoplasmic immunopositivity in the 
SCA patient group compared to control (unpaired, two-tailed t-test 
t(7)  =  3.496, P  =  0.01). ns  =  not significant, **P  <  0.01. Data 
are presented as mean  ±  SEM.
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Figure 2. Extensive abnormal SAFB1 expression in the cytoplasm of 
Purkinje cells in SCA1. The photomicrographs shown are the 
representative images of cerebellar tissue from a post-mortem control 
case of a genetically diagnosed SCA1 patient immunostained for SAFB1. 
In control cerebellum, Purkinje cells in control tissue often feature 
SAFB1 immunostaining within the nucleus, but cytoplasmic SAFB1 
staining is not present (arrow). In SCA1 cerebellum, Purkinje cells have 
cytoplasmic SAFB1 staining in the soma and dendrites (dotted arrow) in 
addition to strong nuclear staining. Cytoplasmic SAFB1 staining appears 
in SCA1 Purkinje cells with mild (i–ii), moderate (iii–iv) and substantial 
(v–vi) morphological alteration in comparison to control Purkinje cells. 
Scale bar is 50 µm.
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characterized SAFB1 staining in a genetically diagnosed 
SCA1 patient (Table S1). SAFB1 immunoreactivity was 
observed within the nuclei of cells within the granular and 
molecular layers of the folia within both control and SCA1 
cerebellum. In control tissue, SAFB1 staining in Purkinje 
cells was limited to within the nuclei and as in SCA patients, 
it was found to be expressed throughout the nucleus (Figures 
1 and 2). In SCA1 Purkinje cells SAFB1 immunoreactivity 
was frequently present in both the nucleus and within the 
cytoplasm of the perikaryon and dendrites (Figure 2 and 
Table S2). Cytoplasmic SAFB1 staining was evident in SCA1 
Purkinje cells with mild, moderate and substantial morpho-
logical alterations (Figure 2).
In addition to atrophy and loss of Purkinje cells within 
the cerebellar cortex, the pathology of polyglutamine SCA 
can also affect the large principle neurons within the dentate 
nucleus of the cerebellar white matter. Notably, SAFB1 
staining was not detected in the dentate neurons in the 
control cases (Figure 3A). However, there was a significantly 
increased expression of SAFB1 in both the nucleus (Figure 
Figure 3. SAFB1 expression is increased in the nucleus and cytoplasm 
of cerebellar dentate nucleus neurons in SCA patients. A. Representative 
images of cerebellar dentate nucleus immunostained for SAFB1 show 
large principle neurons (identifiable by their morphology) within the 
neuropil of the dentate nucleus in control and SCA cases (arrow). Cells 
within SCA patient dentate nucleus appear smaller and shrunken in 
shape (dotted arrow) and show increased nuclear and cytoplasmic 
SAFB1 expression. Numbering represents patient case number, scale 
bar is 50  µm. B-C. SAFB1 Immunoreactivity is expressed as the 
percentage of large principle neurons which are immuno-positive for 
SAFB1 in either the nucleus or the cytoplasm. In SCA patients, a 
significantly higher percentage of neurons are positive for SAFB1 within 
the nuclei compared to control cases (unpaired, two-tailed t-test 
t(7) = 4.675, P = 0.0023) (B). Cytoplasmic SAFB1 is also expressed in a 
significantly higher percentage of neurons of SCA patients compared to 
control cases (unpaired, two-tailed t-test t(7) = 4.253, P = 0.0038) (C). 
**P < 0.01, ***P < 0.001. Data are presented as mean ± SEM.
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3A,B) and cytoplasm (Figure 3A,C) of dentate nuclei neu-
rons in SCA patients (Table S2). The dentate nuclei neurons 
of SCA patients appeared smaller and shrunken and SAFB1 
staining was diffused and distributed throughout the cell 
bodies (Figure 3A and Table S2) as in Purkinje cells. There 
is, however, less dentate neuron cell loss compared to that 
seen for Purkinje cells. Taken together, these data shows 
that abnormal cytoplasmic SAFB1 expression is a feature 
of two neuronal populations specifically affected by poly-
glutamine-induced neurodegenerative damage in SCA.
To confirm that cytoplasmic SAFB1 staining was specific 
to Purkinje cells, dual immunofluorescent labeling was per-
formed using antibodies against SAFB1 and calbindin-D28k 
(a calcium-binding protein which is widely used as a Purkinje 
cell marker). Representative images show that cytoplasmic 
SAFB1 was present in cerebellar Purkinje cells, as determined 
by co-localization with calbindin immunoreactivity 
(Figure 4A). To assess whether cytoplasmic SAFB1 expression 
was localized to injured or damaged Purkinje cells in SCA, 
cerebellar sections were dual labeled for SAFB1 and SMI-34. 
SMI-34 is raised against hyperphosphorylated neurofilaments 
(Covance, USA) and been found to recognize intraneuronal 
pathological Tau paired helical filaments (PHF-tau/Alzheimer 
disease tangles) (32) and to be a marker of Purkinje cell 
damage in post-mortem human brain (33). SCA Purkinje 
cells featuring hallmark morphological features of neurode-
generative injury (such as reduced perikaryon size and a 
deflated appearance to the nucleus) positive for SMI-34 stain-
ing also contained abnormal cytoplasmic SAFB1 expression 
(Figure 4B). Immunofluorescent images show increased cyto-
plasmic SAFB1 staining relative to nuclear staining. This is 
likely a feature of the immunofluorescent staining, though 
it may also result from the low levels of SAFB1 staining 
seen in the nuclei of some control patients (Figure S3).
Previous studies have shown that Purkinje cell degeneration 
and loss occurs in patients with multiple sclerosis (MS) (33,45). 
Therefore, to assess whether abnormal cytoplasmic SAFB1 
expression is specifically associated with Purkinje cell injury 
induced by polyglutamine disease, cerebellar tissue sections 
from four patients diagnosed with multiple sclerosis were 
immunolabeled for SAFB1. Multiple sclerosis causes Purkinje 
cell damage and degeneration, but this is not caused by poly-
glutamine pathology. Analysis of Purkinje cells across whole 
cerebellar sections including those with a dystrophic phenotype 
showed that SAFB1 immunostaining was confined to the 
nucleus, following the same pattern to that of control patients 
(Figure 5). We also immunostained substantia nigra sections 
with SAFB1 and found there was no difference in expression 
between controls and Parkinson’s patients (Figure S4).
The neuropathology of autosomal dominant spinocerebellar 
ataxias caused by polyglutamine expansion repeats has been 
well characterized and frequent pathological hallmarks include 
a reduction in the number of Purkinje cells (Table S1) and 
reduction in Purkinje cell size. To determine whether there 
was a relationship between Purkinje cell histopathological 
characteristics and the frequency of SAFB1 staining, Pearson 
correlative analysis was carried out (Figure 6). There was 
no significant correlation between Purkinje cell perikaryon 
area and nuclear SAFB1 staining (Figure 6A). However, 
there was a significant correlation between SAFB1 staining 
in the cytoplasm and Purkinje cell perikaryon area (Figure 
6B). Taken together the data show that increasing frequency 
of abnormal SAFB1 in the cytoplasm is associated with 
Purkinje cell injury, as measured by shrinkage of the cell 
soma and loss of cell number. In a single SCA case, who 
died as a result of cancer, there was a larger number of 
surviving Purkinje cells (compared to 4 other SCA patients, 
Table S1) and over 56% of these cells stained positive for 
cytoplasmic SAFB1. The presentation of SAFB1 pathology 
in this single SCA case suggests that changes in SAFB1 
expression occur relatively early in the disease process.
We used individual-nucleotide resolution crosslinking 
and immunoprecipitation (iCLIP) to identify SAFB1 RNA 
binding partners and found that ATXN1 RNA contained 
the greatest number of  SAFB1 RNA binding sites 
(Figure 7A). The SAFB1 iCLIP tags all mapped to ATXN1 
RNA encoded by exon 8 and the crosslink sites indicated 
SAFB1 bound ATXN1 primarily at the start of  the CAG 
Figure 4. SAFB1 colocalizes with calbindin and SMI-34 in the cytoplasm 
of SCA Purkinje cells. A. Calbindin immunopositivity specifies Purkinje 
cell soma and dendrites. SAFB1 staining is absent from the cytoplasm 
of control Purkinje cells but is colocalized with calbindin in SCA cases 
(arrows). Cell nuclei were stained using DAPI (blue). B. SMI-34 staining, 
a marker of Purkinje cell damage colocalizes with SAFB1 in the soma 
and dendrites of SCA cerebellum (arrows) but not control tissue. SMI-34 
also stains basket cell projections (asterisk), which appear hypertrophied 
in SCA tissue compared to control. Scale bar is 50 µm.
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repeat region (Figure 7B), though sites were also found 
within the CAG repeats. In addition, our results showed 
that SAFB1 bound antisense ATXN1 (ATXN-AS1) 
RNA within the GTC repeat region (31). To investigate 
whether increasing the number of  CAG repeats would 
alter SAFB1 binding, we transfected neuroblastoma cells 
with constructs encoding full-length ATXN1 mRNA con-
structs with either 30 (control ATXN1-30Q) or 85 poly-
glutamine (disease ATXN1-85Q) repeats (ref) and carried 
out SAFB1 immunoprecipitation followed by qPCR for ATXN1 
(Figure 7C). Our results showed that SAFB1 bound 
non-pathogenic ATXN1-30Q mRNA, however, this asso-
ciation was significantly increased when there was a patho-
logical polyQ expansion (ATXN85Q). To control for binding 
mediated by endogenously expressed ATXN1 in HeLa cells, 
control cells not transfected with an ATXN1 plasmid were 
included in each experiment. In these experiments, qPCR 
analysis showed that the relative quantity of  endogenous 
ATXN1 RNA bound to SAFB1 protein in non-transfected 
cells was extremely low (compared to that in cells 
expressing exogenous ATXN1) and did not complicate 
interpretation of  the assay. In addition to this data, we 
Figure 5. SAFB1 expression is unaltered in the dystrophic Purkinje cells 
of MS patients. Cerebellar Purkinje cells in patients with MS 
immunostained for SAFB1 (representative images from n = 4 patients, 
scale bar is 25 µm). SAFB1 staining within Purkinje cells with a typically 
dystrophic phenotype is nuclear without immunoreactivity in the 
cytoplasm of the cell soma or dendrites. The percentage of Purkinje 
cells positive for SAFB1 staining in the nucleus in each patient group is 
as follows (mean ± SEM); Control (72.2 ± 5.6), MS (83.3 ± 10.7), SCA 
(77.1 ± 8.6). The percentage of Purkinje cells positive for SAFB1 in the 
cytoplasm per group is as follows; Control (1.4 ± 0.6), MS (5.1 ± 1.9) 
SCA (46.2 ± 11.3).
Figure 6. SAFB1 expression correlates with decreased Purkinje cell 
area in SCA patients. There was no significant correlation between 
SAFB1 staining in the nucleus and Purkinje cell area (A). However, 
increased cytoplasmic SAFB1 staining was correlated significantly with 
a decrease in Purkinje cell perikaryon area (B). Statistical analyses were 
carried out using Pearson correlation tests and the P and r values are 
depicted within each graph.
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have conducted a TMT proteomic analysis of  proteins 
pull-down with a SAFB1 specific antibody and we did 
not find SAFB1 bound ATXN1 protein (unpublished obser-
vations). Furthermore, when EGFP tagged ATXN1 con-
structs with 2, 30 and 52Q repeats are expressed in 
neuroblastoma cells they do not bind SAFB1 (unpublished 
observations).
SAFB1 expression is abnormal in striatal 
Huntington’s disease neurons
As SAFB1 protein expression has not previously been char-
acterized in any human polyglutamine disorders, following 
our findings in SCA, we next investigated SAFB1 expression 
in HD, the most common neurodegenerative disease caused 
by CAG expansion repeats. Post-mortem striatal tissue was 
obtained from a cohort of patients diagnosed with HD 
(ranging between Vonsattel grade 2-4) and from control 
cases with no history of neurological disease (Figure 8A,B, 
Table 1). There was no significant difference in age 
(t(13)  =  0.69, P  =  0.5) or post-mortem delay (t(13)  =  0.92, 
P  =  0.38) when HD patients were compared to controls 
(unpaired, two-tailed t-tests). SAFB1 immunostaining was 
evident in the nuclei of striatal cells and there was no 
significant difference in the number of cells positive for 
nuclear SAFB1 in HD patient tissue compared to control 
(Figure 8C). However, in Huntington’s cases, strong cyto-
plasmic SAFB1 staining was present in the cells of the 
striatum and this was not found in controls (Figure 8D). 
In addition, the SAFB1 staining in the cytoplasm was found 
to occur mainly in large dystrophic cells (presumably medium 
spiny neurons) and this was invariably accompanied by 
increased SAFB1 nuclear staining. We next compared the 
frequency and localization of SAFB1 staining with that of 
polyglutamine inclusions. Analysis of low-magnification 
images found that the frequency of abnormal neuronal 
SAFB1 staining and polyglutamine inclusions was similar 
(38.6% and 34.3%, respectively; Figure 9A). High-magnification 
images (Figure 9B) showed that polyglutamine staining was 
present in both the nucleus and cytoplasm of degenerating 
neurons and that it generally presented as concentrated large 
puncta/aggregates. In contrast, SAFB1 staining was more 
homogenous, with strong staining throughout the nucleus 
and an even distribution of staining with small puncta 
present throughout the cytoplasm. These differing staining 
patterns strongly suggest that the SAFB1 protein is not 
closely associated with polyglutamine aggregates in HD 
neurons.
DISCUSSION
In this study, we investigated the expression of the DNA 
and RNA binding protein SAFB1 in the post-mortem human 
brains of SCA, HD, PD and MS patients. We found that 
SAFB1 expression was increased in the nucleus and mislocal-
ized to the cytoplasm in the Purkinje and cerebellar dentate 
Figure 7. Increased binding of SAFB1 to Ataxin 1 with an expanded 
glutamine tract. A. The top 10 most SAFB1 bound RNA transcripts with 
the total number of iCLIP SAFB1 cross-link sites from three independent 
experiments. B. The red line depicts the location of the ATXN1 gene on 
chromosome 6. The majority of the SAFB1 binding sites occur in RNA 
encoded by exon 8 of ATXN1 and in the region containing CAG repeat 
sequence (blue hatched lines). A screengrab taken from the genome 
browser shows the sense (brown) and antisense (blue) SAFB1 iCLIP 
binding sites. The binding sites relative to the amino-acids encoded by 
the SAFB1 bound sequences are shown in a 3′-5′ orientation. Note the 
SAFB1 cross-link site will correspond to the amino-acid most 5′ to the 
sense sequence and 3′ to the antisense sequence. The numbers within 
the schematic of the sense binding sites show the number of SAFB1 
cross-link sites in each of these individual experiments. C i. Western 
blotting of protein lysates from RNA immunoprecipitation experiments, 
probed for SAFB1. SAFB1 is present in both ATXN1-30Q transfected and 
ATXN1-85Q transfected cell lysates immunoprecipitated using a SAFB1 
antibody (IP). There is no SAFB1 protein detected in IgG control lysates 
(IgG). Expected molecular weight for SAFB1 is 102KDa (arrow). ii. 
Relative levels of ATXN1 RNA bound to SAFB1 protein. SAFB1 protein 
was immunoprecipitated from HeLa cells transfected with plasmids 
containing ATXN1-30CAG (physiological) or ATXN1-85CAG (pathological 
expansion). The relative expression level of ATXN1 RNA associated with 
SAFB1 protein is significantly increased in ATXN1-85 CAG compared to 
ATXN1-30 CAG (unpaired, two-tailed t-test t(4) = 3.76, P = 0.01). Data 
are presented as mean ± SEM.
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cells of SCA patients and in the striatal neurons of HD 
patients. We further showed that abnormal SAFB1 cytoplasmic 
expression co-localized with a Purkinje cell-specific marker 
and col-localized with SMI-34 an antibody that labels intra-
neuronal pathological PHF-tau (32) and has correlated with 
Purkinje cell damage (15). Cerebellar dentate cell degeneration 
and loss also occurs in SCA patients (16) and dentate neurons 
displaying a shrunken phenotype correlated with increased 
SAFB1 expression in both the nucleus and cytoplasm. The 
change in nuclear and cytoplasmic SAFB1 expression under 
these disease conditions was dramatic as there was no SAFB1 
staining in the dentate and striatal neurons of control patients. 
Furthermore, studies have shown that Purkinje cell loss and 
the mislocalization of RBPs to the cytoplasm of neurons 
occurs in patients with MS (33,38,45). However, we found 
that there was no abnormal SAFB1 expression in the dys-
trophic Purkinje cells of MS patients or in the substantia 
nigra of PD patients indicating that abnormal SAFB1 may 
be specific to diseases characterized by glutamine expansions. 
Interestingly, in Huntington’s cases, the abnormal SAFB1 
Figure 8  . SAFB1 expression is altered in the striatal neurons of HD 
patients. A. Representative images from individual cases showing the 
distribution of SAFB1 staining within striatal cells in control and HD 
patients. B. A representative higher magnification image showing SAFB1 
staining in control tissue is mostly confined to the nucleus of larger cells 
within the striatum. SAFB1 staining in HD striatum is stronger and 
present in both the nuclei and cytoplasm of larger cells (MSN). Numbers 
in individual photomicrographs represent the patient case number. C. 
There is no significant difference in the number of cells with nuclear 
SAFB1 staining in HD cases compared to controls (unpaired, two-tailed 
t-test t(13) = 1.9, P = 0.08). D. There is a significantly higher number of 
cells positive for cytoplasmic SAFB1 in the striatum of HD patients 
compared to in control cases (unpaired, two-tailed t-test t(13) = 9.266, 
P < 0.0001). Data are presented as mean ± SEM. Scale bars are 25 µm.
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nuclear and cytoplasmic staining pattern differed to that of 
polyglutamine inclusions suggesting the two proteins do not 
interact. However, we did show that SAFB1 binds ATXN1 
RNA adjacent to and within the glutamine repeat region 
and that there was significantly increased SAFB1 binding to 
Ataxin 1 RNA containing an expanded pathogenic polyglu-
tamine tract. This suggests that SAFB1 may bind RNA motifs 
adjacent to polyglutamine tracts and within polyglutamine 
tracts, for example, due to the formation of a G-quadruplex 
structure. RBPs often interact with other RBPs and this 
allows distinct RNA motifs in close proximity to be bound 
simultaneously and increases interaction specificity. Hence, the 
formation of long glutamine tracts may result in an RNA 
structure that creates multiple SAFB1 (and other RBP) bind-
ing sites. We found SAFB1 expression was abnormal in SCA 
and HD patients but was unaltered in MS or PD patients. 
Though it should be noted that while all the SCA patients 
used had extensive cerebellar/Purkinje cell pathology only 
three of the five were confirmed by genetic testing/IC2 immu-
noreactivity as being polyglutamine expansion/inclusion posi-
tive. It is, therefore, important that further studies are conducted 
to investigate SAFB1 pathology in SCA patients with con-
firmed polyglutamine phenotypes. In this regard, it would 
also be informative to investigate the association of SAFB1 
pathology with markers that characterize other non-polyglu-
tamine expansion neurodegenerative conditions. Overall, as 
SAFB1 was strongly associated with HD and SCA disease 
phenotypes and considering the important roles it plays in 
regulating neuronal gene expression these data strongly sug-
gest SAFB1 contributes to the pathology of polyglutamine 
illnesses.
Figure 9. Frequency and localization of SAFB1 staining compared with 
polyglutamine inclusions in HD. A i. No primary antibody control 
staining of striatal tissue from an HD patient (upper panel). 
Polyglutamine immunostaining using antibody 1C2 in the striatum of a 
control patient shows no immunoreactivity (lower panel). ii. 
Representative low-magnification images of polyglutamine and SAFB1 
staining in separate, serial striatal sections of an HD patient (case 23). 
The percentage of neurons positive for cytoplasmic SAFB1 and for 
polyQ is indicated below the images. B. High magnification images 
show that polyQ aggregates/inclusions occur in both the nucleus and 
cytoplasm. SAFB1 staining is generally homogenous, with strong 
staining throughout the nucleus and an even distribution of staining 
with small puncta present throughout the cytoplasm. Scale bar in (A) is 
50 µm, in (B) is 10 µm.
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SAFB1 is a multifunctional DNA and RNA binding protein 
implicated in the control of gene expression (24,35,40), DNA 
repair (2) apoptosis (20) and the formation of nuclear stress 
bodies (7). SAFB1 is known to interact with Sam 68, hnRNP 
K, SRSF1, FUS and Matrin 3 (28,36,46) and these interac-
tion partners have been implicated in the pathology of 
repeat disorders such as Fragile X-associated Tremor/Ataxia 
Syndrome (FXTAS) (39), SCA10 (44) and ALS/FTD 
(10,42,46). Considering the functions of SAFB1, it is evident 
that its upregulation and/or ectopic cytoplasmic expression 
in neurons of patients with polyglutamine expansion disorders 
would contribute to disease pathology. First, the altered 
expression of SAFB1 in the nucleus is likely to result in 
major changes in gene transcription, splicing and RNA trans-
port and these will have major functional consequences. For 
instance, we have shown increased expression of SAFB1 alters 
dendritic function (35). SAFB1 organizes chromatin structure 
via phase separation (12) and the altered SAFB1 expression 
seen in polyglutamine disorders may, therefore, result in changes 
in heterochromatin stability. Mutations in FUS and matrin-3 
are associated with ALS and SAFB1 have been shown to 
regulate the interaction of FUS with chromatin and bind 
directly with Matrin 3 (also a nuclear matrix-associated pro-
tein). Expression of the normally nuclear SAFB1 RNA binding 
protein in the cytoplasm will sequester coding and non-coding 
RNAs and RNA binding proteins and lead to compromised 
neuronal function. In addition, we have shown that the SAFB1 
paralogue, SAFB2 is expressed in axons and dendritic spines 
(28) and hence SAFB1 is likely to interfere with SAFB2 
mediated RNA transport. Recently, the altered expression of 
DNA repair genes was implicated in polyglutamine tract 
expansion and the modification of age of neurological onset 
in HD and SCAs (11,18). SAFB1 renders chromatin permis-
sive to DNA repair and depending on the availability of 
cofactors its upregulation could promote or inhibit DNA 
repair. Investigating whether the up or down-regulation of 
DNA repair modifiers such as SAFB1 accelerated or delayed 
the age of onset in models of HD/SCAs could, therefore, 
identify new therapeutic approaches.
The mechanism by which SAFB1 expression is altered in 
SCA and HD is uncertain. The increased cytoplasmic and 
nuclear SAFB1 expression seen (e.g. in cerebellar neurons 
and dentate neurons, respectively) may be due to: (i) it bind-
ing to transcribed and/or translated polyglutamine repeats; 
(ii) increased transcription mediated by feedback control; 
(iii) association with one or more protein partners altered 
in polyglutamine disorders. We found that there is signifi-
cantly increased binding of SAFB1 to ATXN1 RNA encoding 
an expanded glutamine tract. This suggests that the mislo-
calization (and possibly up-regulation) of SAFB1 may be 
linked to the altered processing and transport of RNA 
containing pathological polyglutamine tracts. This hypothesis 
is supported by the observation that there is altered nucleo-
cytoplasmic transport of RBPs in polyglutamine expansion 
diseases and ALS (3,8). SRSF1 (a known protein-binding 
partner of SAFB1) mediates the export of repeat-RNA to 
the cytoplasm (10). Furthermore, the expression of ALS-
linked FUS mutants has previously been reported to mediate 
the movement of SAFB1, Matrin-3 and FUS to the 
cytoplasm (46). This altered SAFB1 expression could result 
from an inhibition of nuclear import or increased co-export 
with a binding partner. Further studies to identify by what 
mechanism SAFB1 expression is altered and to what degree 
it contributes to early disease pathogenesis may highlight 
new therapeutic approaches for polyglutamine diseases.
CONCLUSIONS
Our novel results show that the important gene regulatory 
protein SAFB1 is abnormally expressed in neurons from 
patients with polyglutamine expansion disorders and its 
altered expression is likely to cause neuronal pathology due 
to a loss of nuclear function and/or gain of function in 
the cytoplasm. Considering SAFB1 interacts with proteins 
(e.g. Sam 68, Matrin 3, hnRNP K & SRSF1) implicated 
in the etiology of human neurodegenerative conditions, these 
findings support the hypothesis that altering the intercon-
nected networks of RNA binding proteins strongly contributes 
to the etiology of human neurodegenerative conditions.
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SUPPORTING INFORMATION
Additional supporting information may be found in the online 
version of this article at the publisher’s web site:
Figure S1. SAFB antibody controls. Lysate from HeLa cells 
transfected with siRNAs against SAFB1 or SAFB2 was run 
by SDS-PAGE and probed using antibodies against SAFB1 or 
SAFB2 (A). Both antibodies specifically recognise a reduction 
in SAFB1 expression. No primary antibody control striatal 
and cerebellar tissue sections have no DAB reactivity, indicat-
ing that there is no non-specific detection from either the ABC 
detection system or from the sections themselves (B). Scale 
bars are 50 μm.
Figure S2. SAFB1 staining in the cerebellum of control and 
SCA patients (higher magnification images are shown in 
Figure 1). These representative images show Purkinje cell 
staining in relation to the cerebellar molecular and granule cell 
layers. Inset numbering represents the patient case number. 
Scale bar = 50 μm.
Figure S3. SAFB1 staining of cerebellar control patient sec-
tions. (A) A control patient Purkinje cell positive for SAFB1 
immunofluorescent nuclear staining. Arrows indicates 
Purkinje cell nucleus. GL = granule cell layer. (B) Control 
patient Purkinje cells negative for SAFB1 expression in the 
nucleus (immunohistochemical DAB staining). Arrow indi-
cates Purkinje cell nucleus. GL = granule cell layer.
Figure S4. Formalin fixed paraffin embedded sections from 
control and Parkinson’s disease (PD) substantia nigra, immu-
nostained for SAFB1. Overall levels of SAFB1 staining in the 
substantia nigra are low compared to the cerebellum and stria-
tum. There is no clear difference in nuclear SAFB1 staining in 
control patients compared to PD patients. There is no evidence 
of cytoplasmic SAFB1 staining in control or PD patient sub-
stantia nigra. 40× scale bar is 50 μM, magnified region scale 
bar is 25 μm.
Table S1. Spinocerebellar ataxia (SCA) patient diagnosis and 
pathology data.
Table S2. Purkinje and dentate neurons counted and num-
ber of cells positive for nuclear and/or cytoplasmic SAFB1 
staining.
